(1S,4R)-2-(tert-Butoxycarbonyl)-2-azabicyclo[2.1.1]hexane-5-carboxylic acid

Catalog No. :
ACSLAD793
CAS No. :
1250883-94-3
Molecular Formula :
C11H17NO4
Molecular Weight :
227.26

IUPAC Name:(1S,4R)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.1.1]hexane-5-carboxylic acid

(1S,4R)-2-(tert-Butoxycarbonyl)-2-azabicyclo[2.1.1]hexane-5-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$765.00Login to see priceInquiryInquiry
1g97%$1912.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(1S,4R)-2-(tert-Butoxycarbonyl)-2-azabicyclo[2.1.1]hexane-5-carboxylic acid
IUPAC Name(1S,4R)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.1.1]hexane-5-carboxylic acid
MDL No.MFCD29920689
Molecular FormulaC11H17NO4
Molecular Weight227.26
SMILESO=C(C1[C@]2([H])CN(C(OC(C)(C)C)=O)[C@@]1([H])C2)O
InChI KeyVGONMHFNYUTBCO-WPZUCAASSA-N
Synonym(1S,4R)-2-(TERT-BUTOXYCARBONYL)-2-AZABICYCLO[2.1.1]HEXANE-5-CARBOXYLIC ACID;2-Azabicyclo[2.1.1]hexane-2,5-dicarboxylic acid, 2-(1,1-dimethylethyl) ester, (1R,4S)-rel-
CAS No.1250883-94-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACSLAD793 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSLAD793 route product structure diagram
    ACSLAD7931250883-94-3
Inquiry

2. ACSLAD793 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSLAD793 route product structure diagram
    ACSLAD7931250883-94-3
Inquiry

Comments (0)